''Motion-preservation'' Spine Company Applied Spine Technologies Appoints Chief Medical Officer: Michael J. Giordano, MD, MBA -- Dr. Giordano will oversee ongoing clinical trial of the "motion preserving" Stabilimax NZ(R) spinal device to treat the most common indication for surgery in persons over 60: Lumbar Spinal Stenosis (LSS)

Share Article

Applied Spine Technologies ("AST") announced today that it has appointed neurosurgeon Michael J. Giordano, MD, MBA, as its Chief Medical Officer, effective immediately. Dr. Giordano will oversee an ongoing, randomized, controlled, national clinical study of its "motion preserving" Stabilimax NZ(R) Dynamic Spine Stabilization System. The study is comparing posterior dynamic stabilization in patients using the Stabilimax NZ device to patients receiving traditional fusion surgery to treat their Lumbar Spinal Stenosis, a common lower-back disorder where deterioration of the joints and discs leads to increased pressure on the spinal nerves.

News Image
We are extremely pleased to have Dr. Giordano join us, particularly at this time, as we continue to ramp up patient enrollment for our Stabilimax NZ clinical trial at 20 sites across the country

    Most recently, Dr. Giordano was a consultant to medical device companies and private equity investors. Previously, he was a neurosurgeon in clinical, clinical academic, and group community practices since 1998. Dr. Giordano received his degree in medicine from New York University School of Medicine in 1986, and a master's degree in business administration from Yale University School of Management in 2007. He has published research in the peer-reviewed journals Surgical Neurology, Journal of Neurochemistry, Journal of Neuroscience Research, Oncogene and American Journal of Pathology. Dr. Giordano is a captain in the U.S. Naval Reserve and a Certified Navy Diver.

"We are extremely pleased to have Dr. Giordano join us, particularly at this time, as we continue to ramp up patient enrollment for our Stabilimax NZ clinical trial at 20 sites across the country," said Thomas E. Wood, President and CEO of Applied Spine Technologies. "Spine fusion used to be the only option for patients suffering from chronic back pain. Stabilimax NZ is designed to be a dramatic advance in back pain treatment by stabilizing the spine without eliminating motion."

Lumbar Spinal Stenosis is the most common indication for surgery in persons aged over 60 in the United States. It is estimated that as many as 400,000 Americans, most over the age of 60, may already be suffering from the symptoms of LSS (source: American Association of Neurological Surgeons (AANS) and Congress of Neurological Surgeons (CNS)), and this number is expected to grow over the next decade.

For further information, please visit http://www.appliedspine.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ronald C. Trahan
Visit website